Competitive IntelligenceCI-003Publishedv1.0.0

Market Access Evidence Pack

Build the value story payers need to hear

~35s runtime3 evidence sources3 regulatory mappingsUpdated Dec 2025

Summary

Compiles health economics data, payer landscape analysis, and reimbursement precedents to support market access strategy and value dossier development.

Detailed Description

The Market Access Evidence Pack supports sponsors in developing evidence-based market access strategies and payer value propositions. It aggregates health economics data, payer coverage policies, reimbursement precedents, and health technology assessment (HTA) outcomes to inform pricing, market access planning, and value dossier development.

The pack analyzes the payer landscape for your therapeutic area, including commercial and government payer coverage policies, formulary placement patterns, and prior authorization requirements. It benchmarks pricing and access outcomes for analogous products and identifies the evidence requirements for favorable payer decisions.

Deliverables include a market access landscape assessment, a value dossier framework with evidence gap analysis, and a pricing and reimbursement benchmarking analysis across comparable therapies in your indication.

Evidence Sources

SourceTypeDescriptionRefresh
Health Economics DatabaseLITERATUREPublished cost-effectiveness analyses, budget impact models, and health economics studiesWeekly
Payer Coverage DatabaseCURATEDCommercial and Medicare/Medicaid coverage policies, formulary data, and utilization management criteriaMonthly
HTA Decision DatabaseREGULATORYHealth technology assessment decisions from NICE, ICER, CADTH, and other HTA bodiesMonthly

Regulatory Mapping

NICENICE Methods Guide

Guide to the Methods of Technology Appraisal

PRIMARY
ICERICER Value Framework

ICER Value Assessment Framework

PRIMARY
ISPORISPOR Good Practices

ISPOR Good Practices for Outcomes Research

SECONDARY

Agent Transparency

When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.

🔍

Evidence Retriever

brew-retriever-v3

Step 1

Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.

Confidence floor: 85%Avg latency: 4-8s
🧬

Domain Analyzer

brew-domain-analyst-v2

Step 2

Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.

Confidence floor: 80%Avg latency: 6-12s
📊

Evidence Synthesizer

brew-synthesizer-v2

Step 3

Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.

Confidence floor: 82%Avg latency: 8-15s

Output Validator

brew-validator-v1

Step 4

Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.

Confidence floor: 90%Avg latency: 2-4s

Sample Outputs

Market Access Landscape Assessment

PDF

Comprehensive assessment of the payer landscape including coverage policies and access barriers

Value Dossier Framework

DOCX

AMCP-format value dossier framework with evidence gap analysis and data generation recommendations

Pricing & Reimbursement Benchmarking

XLSX

Comparative pricing and reimbursement analysis across analogous therapies in the target indication

Deliverables included

  • Market access landscape assessment
  • AMCP-format value dossier framework
  • Pricing and reimbursement benchmarking analysis
  • Evidence gap analysis for payer decision-making
  • HTA submission strategy and timeline

Related Disease & Biomarker Mappings

Therapeutic AreaDisease FamilyKey BiomarkersRelevance
Cross-TherapeuticPipeline Competitive Landscape
Market differentiation markers
Primary
OncologyIO Competitive Landscape
PD-(L)1 AgentsLAG-3TIGIT
Secondary

Related Packs in Competitive Intelligence

Version History

v1.0.0CurrentNovember 14, 2025

Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.

v0.9.0October 15, 2025

Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.

v0.1.0September 15, 2025

Initial draft — core evidence retrieval pipeline and output schema established.

Need a Custom Evidence Pack?

Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.

Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.